498532-06-2

Basic information

• Product Name: Benzenepentanoic acid, 4-fluoro-b-oxo-, ethyl ester
• CAS NO: 498532-06-2
• Molecular Formula: C13H15FO3
• Molecular Weight: 238.259
• Mol File: 498532-06-2.mol

Chemical Properties

• CAS DataBase Reference: Benzenepentanoic acid, 4-fluoro-b-oxo-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenepentanoic acid, 4-fluoro-b-oxo-, ethyl ester(498532-06-2)
• EPA Substance Registry System: Benzenepentanoic acid, 4-fluoro-b-oxo-, ethyl ester(498532-06-2)

Safety Data

• Hazardous Substances Data: 498532-06-2(Hazardous Substances Data)

Upstream product

• 772-70-3 3-(4-fluorophenyl)propanoyl chloride 
• 141-97-9 ethyl acetoacetate 
• 459-46-1 4-Fluorobenzyl bromide 
• 603999-08-2 5-[3-(4-fluorophenyl)propanoyl]-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 64-17-5 ethanol 
• 459-31-4 3-(4-fluorophenyl)propanoic acid 

Downstream Products

• 858671-11-1 5-[2-(ethoxy)carbonyl-5-(4-fluorophenyl)-3-oxo-1-penten-1-yl] furan-2-carboxylic acid 
• 858671-10-0 5-[2-(ethoxy)carbonyl-5-(4-fluorophenyl)-3-oxo-1-penten-1-yl] thiophene-2-carboxylic acid 
• 603999-18-4 ethyl (2Z)-3-amino-5-(4-fluorophenyl)-2-pentenoate 
• 498532-07-3 (S)-5-(4-fluoro-phenyl)-3-hydroxy-pentanoic acid ethyl ester 
• 603999-11-7 4-{3-[(ethoxy)carbonyl]-2-[2-(4-fluorophenyl)ethyl]-5-oxo-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridin-4-yl}benzoic acid 
• 603999-10-6 4-{3-[(ethoxy)carbonyl]-2-[2-(4-fluorophenyl)ethyl]-5-oxo-1,5,8,9-tetrahydro-4H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridin-4-yl}benzoic acid 
• 858671-15-5 5-{3-[(ethoxy)carbonyl]-2-[2-(4-fluorophenyl)ethyl]-5-oxo-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridin-4-yl}thiophene-2-carboxylic acid 
• 858671-12-2 5-{3-[(ethoxy)carbonyl]-2-[2-(4-fluorophenyl)ethyl]-5-oxo-1,5,8,9-tetrahydro-4H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridin-4-yl}thiophene-2-carboxylic acid 
• 858671-16-6 5-{3-[(ethoxy)carbonyl]-2-[2-(4-fluorophenyl)ethyl]-5-oxo-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridin-4-yl}furan-2-carboxylic acid 
• 858671-13-3 5-{3-[(ethoxy)carbonyl]-2-[2-(4-fluorophenyl)ethyl]-5-oxo-1,5,8,9-tetrahydro-4H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridin-4-yl}furan-2-carboxylic acid 
• 603999-09-3 4-[2-(ethoxy)carbonyl-5-(4-fluorophenyl)-3-oxo-1-penten-1-yl]benzoic acid 

Relevant articles and documents

Modulators of calcitonin and amylin receptor activity

In various aspects, the present invention relates to non-peptidic compounds, which modulate calcitonin and amylin receptor activity; to processes for the preparation of some such compounds; and to pharmaceutical compositions including such compounds. Compounds of the invention are useful as calcitonin and/or amylin agonists and in the treatment of bone diseases and metabolic diseases.

Hantzsch synthesis of pyrazolo[1′,2′:1,2]pyrazolo[3,4-b] pyridines: Partial agonists of the calcitonin receptor

Small molecule calcitonin receptor agonists are of potential utility in the treatment and prevention of osteoporosis. Bicycloeneamine 1 was a useful intermediate in the synthesis of pyrazolopyridine calcitonin receptor partial agonists 2a-f. Dihydropyridi

MODULATORS OF CALCITONIN AND AMYLIN ACTIVITY

In various aspects, the present invention relates to novel compounds, which modulate calcitonin and amylin receptor activity; to processes for the preparation of such compounds; and to pharmaceutical compositions including such compounds. Compounds of the

Synthetic derivatives

This invention features a 5,6-dihydro-2-pyrone compound of formula (I), wherein R1 is H, OH, or C2?C5 alkoxyl; and R2 is 2-phenyl ethyl, 2-phenyl ethenyl, 2-heteroaryl ethyl, or 2-heteroaryl ethenyl; in which th

Asymmetric synthesis of kavalactones

This invention relates to preparation of enantio-enriched compounds, and more particularly to enantio-enriched kavalactone compounds and derivatives thereof. The methods provide compounds that are useful as reagents, or building blocks, in the constructio

CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS

The present invention relates to novel fused heterocyclic ring system compounds and methods for their use in the treatment and prevention of diseases or conditions which are related to irregular calcification.